DAVID KORMAN: Open Payments
NPI 1942204755 · CANTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,084 in 125 payments from 11 companies in 2025. Trend: 2023 $1,793 · 2024 $1,643 · 2025 $2,084
Food & beverage: $1,980Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 23 | $388 |
| ABBVIE INC. | 17 | $298 |
| E.R. Squibb & Sons, L.L.C. | 18 | $258 |
| Neurocrine BioSciences, Inc. | 15 | $257 |
| Vanda Pharmaceuticals Inc. | 19 | $207 |
| Otsuka America Pharmaceutical, Inc. | 7 | $181 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| Alkermes, Inc. | 6 | $110 |
| Lundbeck LLC | 5 | $99 |
| Axsome Therapeutics, Inc. | 6 | $98 |
Products named: VRAYLAR, REXULTI, COBENFY, INGREZZA, FANAPT, AUSTEDO XR, CAPLYTA, ARISTADA.
Industry payments across TX — which companies pay providers there.
